{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T05:32:14Z","timestamp":1794461534498,"version":"4.9.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006386","name":"Adenoid Cystic Carcinoma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006386","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adenoid cystic carcinoma (ACC) is an aggressive salivary gland malignancy with limited treatment options for recurrent or metastatic disease. Due to chemotherapy resistance and lack of targeted therapeutic approaches, current treatment options for the localized disease are limited to surgery and radiation, which fails to prevent locoregional recurrences and distant metastases in over 50% of patients. Approximately 20% of patients with ACC carry NOTCH-activating mutations that are associated with a distinct phenotype, aggressive disease, and poor prognosis. Given the role of NOTCH signaling in regulating tumor cell behavior, NOTCH inhibitors represent an attractive potential therapeutic strategy for this subset of ACC. AL101 (osugacestat) is a potent \u03b3-secretase inhibitor that prevents activation of all four NOTCH receptors. While this investigational new drug has demonstrated antineoplastic activity in several preclinical cancer models and in patients with advanced solid malignancies, we are the first to study the therapeutic benefit of AL101 in ACC. Here, we describe the antitumor activity of AL101 using ACC cell lines, organoids, and patient-derived xenograft models. Specifically, we find that AL101 has potent antitumor effects in in vitro and in vivo models of ACC with activating<jats:italic>NOTCH1<\/jats:italic>mutations and constitutively upregulated NOTCH signaling pathway, providing a strong rationale for evaluation of AL101 in clinical trials for patients with NOTCH-driven relapsed\/refractory ACC.<\/jats:p>","DOI":"10.1038\/s41419-022-05133-9","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T05:02:36Z","timestamp":1659675756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling"],"prefix":"10.1038","volume":"13","author":[{"given":"Renata","family":"Ferrarotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasudha","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Herz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6106-2307","authenticated-orcid":false,"given":"Adar","family":"Yaacov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3325-0332","authenticated-orcid":false,"given":"Oz","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Mondshine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Motin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Leibovich-Rivkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari J.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alka","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon C.","family":"Aster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1361-3231","authenticated-orcid":false,"given":"Nishant","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3500-5664","authenticated-orcid":false,"given":"Evgeny","family":"Izumchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"5133_CR1","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/hed.23925","volume":"38","author":"PM Dillon","year":"2016","unstructured":"Dillon PM, Chakraborty S, Moskaluk CA, Joshi PJ, Thomas CY. Adenoid cystic carcinoma: a review of recent advances, molecular targets, and clinical trials. Head Neck. 2016;38:620\u20137.","journal-title":"Head Neck"},{"key":"5133_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1158\/1940-6207.CAPR-15-0316","volume":"9","author":"EM Rettig","year":"2016","unstructured":"Rettig EM, Talbot CC Jr, Sausen M, Jones S, Bishop JA, Wood LD, et al. Whole-genome sequencing of salivary gland adenoid cystic carcinoma. Cancer Prev Res (Phila). 2016;9:265\u201374.","journal-title":"Cancer Prev Res (Phila)"},{"key":"5133_CR3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/ng.2643","volume":"45","author":"AS Ho","year":"2013","unstructured":"Ho AS, Kannan K, Roy DM, Morris LG, Ganly I, Katabi N, et al. The mutational landscape of adenoid cystic carcinoma. Nat Genet. 2013;45:791\u20138.","journal-title":"Nat Genet"},{"key":"5133_CR4","doi-asserted-by":"crossref","unstructured":"Chahal M, Pleasance E, Grewal J, Zhao E, Ng T, Chapman E, et al. Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making. Cold Spring Harb Mol Case Stud. 2018;4:a002626.","DOI":"10.1101\/mcs.a002626"},{"key":"5133_CR5","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1172\/JCI67201","volume":"123","author":"PJ Stephens","year":"2013","unstructured":"Stephens PJ, Davies HR, Mitani Y, Van Loo P, Shlien A, Tarpey PS, et al. Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest. 2013;123:2965\u20138.","journal-title":"J Clin Invest"},{"key":"5133_CR6","doi-asserted-by":"publisher","first-page":"66239","DOI":"10.18632\/oncotarget.11288","volume":"7","author":"PT Wysocki","year":"2016","unstructured":"Wysocki PT, Izumchenko E, Meir J, Ha PK, Sidransky D, Brait M. Adenoid cystic carcinoma: emerging role of translocations and gene fusions. Oncotarget. 2016;7:66239\u201354.","journal-title":"Oncotarget"},{"key":"5133_CR7","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1158\/1078-0432.CCR-20-1192","volume":"27","author":"R Ferrarotto","year":"2021","unstructured":"Ferrarotto R, Mitani Y, McGrail DJ, Li K, Karpinets TV, Bell D, et al. Proteogenomic analysis of salivary adenoid cystic carcinomas defines molecular subtypes and identifies therapeutic targets. Clin Cancer Res. 2021;27:852\u201364.","journal-title":"Clin Cancer Res"},{"key":"5133_CR8","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1172\/JCI128227","volume":"129","author":"AS Ho","year":"2019","unstructured":"Ho AS, Ochoa A, Jayakumaran G, Zehir A, Valero Mayor C, Tepe J, et al. Genetic hallmarks of recurrent\/metastatic adenoid cystic carcinoma. J Clin Invest. 2019;129:4276\u201389.","journal-title":"J Clin Invest"},{"key":"5133_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1146\/annurev-pathol-052016-100127","volume":"12","author":"JC Aster","year":"2017","unstructured":"Aster JC, Pear WS, Blacklow SC. The varied roles of Notch in cancer. Annu Rev Pathol. 2017;12:245\u201375.","journal-title":"Annu Rev Pathol"},{"key":"5133_CR10","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1126\/science.284.5415.770","volume":"284","author":"S Artavanis-Tsakonas","year":"1999","unstructured":"Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770\u20136.","journal-title":"Science"},{"issue":"Pt 10","key":"5133_CR11","first-page":"2135","volume":"126","author":"K Hori","year":"2013","unstructured":"Hori K, Sen A, Artavanis-Tsakonas S. Notch signaling at a glance. J Cell Sci. 2013;126(Pt 10):2135\u201340.","journal-title":"J Cell Sci"},{"key":"5133_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1158\/1940-6207.CAPR-14-0257","volume":"8","author":"E Izumchenko","year":"2015","unstructured":"Izumchenko E, Sun K, Jones S, Brait M, Agrawal N, Koch W, et al. Notch1 mutations are drivers of oral tumorigenesis. Cancer Prev Res (Phila). 2015;8:277\u201386.","journal-title":"Cancer Prev Res (Phila)"},{"key":"5133_CR13","doi-asserted-by":"crossref","unstructured":"Schubert AD, Zamuner FT, London NR, Zhavoronkov A, Mehra R, Hoque MO, et al. Role of the NOTCH signaling pathway in head and neck cancer. In: Burtness B, Golemis EA, editors. Molecular Determinants of Head and Neck Cancer. Cham: Current Cancer Research. Humana Press; 2018, p 229\u201348. https:\/\/link.springer.com\/chapter\/10.1007\/978-3-319-78762-6_8.","DOI":"10.1007\/978-3-319-78762-6_8"},{"key":"5133_CR14","doi-asserted-by":"publisher","first-page":"81725","DOI":"10.18632\/oncotarget.20879","volume":"8","author":"R Ferrarotto","year":"2017","unstructured":"Ferrarotto R, Heymach JV. Taking it up a NOTCH: a novel subgroup of ACC is identified. Oncotarget. 2017;8:81725\u20136.","journal-title":"Oncotarget"},{"key":"5133_CR15","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1200\/JCO.2016.67.5264","volume":"35","author":"R Ferrarotto","year":"2017","unstructured":"Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, et al. Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors. J Clin Oncol. 2017;35:352\u201360.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"5133_CR16","doi-asserted-by":"publisher","first-page":"6072","DOI":"10.1200\/JCO.2021.39.15_suppl.6072","volume":"39","author":"BS Hapuarachi","year":"2021","unstructured":"Hapuarachi BS, Feeney L, Rack S, Adderley H, Morgan D, Betts G, et al. Clinical disease course and survival outcomes following disease recurrence in adenoid cystic carcinoma (ACC) with NOTCH signaling pathway activation. J Clin Oncol. 2021;39(15_suppl):6072.","journal-title":"J Clin Oncol"},{"key":"5133_CR17","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/carcin\/bgt127","volume":"34","author":"KM Capaccione","year":"2013","unstructured":"Capaccione KM, Pine SR. The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis. 2013;34:1420\u201330.","journal-title":"Carcinogenesis"},{"key":"5133_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2008.09.030","volume":"279","author":"Z Wang","year":"2009","unstructured":"Wang Z, Li Y, Banerjee S, Sarkar FH. Emerging role of Notch in stem cells and cancer. Cancer Lett. 2009;279:8\u201312.","journal-title":"Cancer Lett"},{"key":"5133_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ccr.2005.06.004","volume":"8","author":"Q Zeng","year":"2005","unstructured":"Zeng Q, Li S, Chepeha DB, Giordano TJ, Li J, Zhang H, et al. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell. 2005;8:13\u201323.","journal-title":"Cancer Cell"},{"key":"5133_CR20","first-page":"671","volume":"23","author":"F Gu","year":"2010","unstructured":"Gu F, Ma Y, Zhang Z, Zhao J, Kobayashi H, Zhang L, et al. Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep. 2010;23:671\u20136.","journal-title":"Oncol Rep"},{"key":"5133_CR21","doi-asserted-by":"crossref","unstructured":"Wu CX, Xu A, Zhang CC, Olson P, Chen L, Lee TK, et al. Notch inhibitor PF-03084014 inhibits hepatocellular carcinoma growth and metastasis via suppression of cancer stemness due to reduced activation of Notch1-Stat3. Mol Cancer Ther. 2017;16:1531\u201343.","DOI":"10.1158\/1535-7163.MCT-17-0001"},{"key":"5133_CR22","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1021\/acsmedchemlett.5b00001","volume":"6","author":"AV Gavai","year":"2015","unstructured":"Gavai AV, Quesnelle C, Norris D, Han WC, Gill P, Shan W, et al. Discovery of clinical candidate BMS-906024: a potent Pan-Notch inhibitor for the treatment of leukemia and solid tumors. ACS Med Chem Lett. 2015;6:523\u20137.","journal-title":"ACS Med Chem Lett"},{"key":"5133_CR23","doi-asserted-by":"crossref","unstructured":"Mohamed AA, Tan S-H, Xavier CP, Katta S, Huang W, Ravindranath L, et al. Synergistic activity with NOTCH inhibition and androgen ablation in ERG-positive prostate cancer cells. Mol Cancer Res. 2017;15:1308\u201317.","DOI":"10.1158\/1541-7786.MCR-17-0058"},{"key":"5133_CR24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/sctm.16-0335","volume":"6","author":"S Barat","year":"2017","unstructured":"Barat S, Chen X, Cuong Bui K, Bozko P, Gotze J, Christgen M, et al. Gamma-secretase inhibitor IX (GSI) impairs concomitant activation of Notch and Wnt-beta-catenin pathways in CD44+ gastric cancer stem cells. Stem Cells Transl Med. 2017;6:819\u201329.","journal-title":"Stem Cells Transl Med"},{"key":"5133_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/978-1-4939-1139-4_23","volume":"1187","author":"GE De Kloe","year":"2014","unstructured":"De Kloe GE, De Strooper B. Small molecules that inhibit Notch signaling. Methods Mol Biol. 2014;1187:311\u201322.","journal-title":"Methods Mol Biol"},{"key":"5133_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2015.11.021","volume":"56","author":"S Pant","year":"2016","unstructured":"Pant S, Jones SF, Kurkjian CD, Infante JR, Moore KN, Burris HA, et al. A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer. Eur J Cancer. 2016;56:1\u20139.","journal-title":"Eur J Cancer"},{"key":"5133_CR27","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/j.1601-0825.2006.01334.x","volume":"13","author":"J Yao","year":"2007","unstructured":"Yao J, Duan L, Fan M, Wu X. Gamma-secretase inhibitors exerts antitumor activity via down-regulation of Notch and Nuclear factor kappa B in human tongue carcinoma cells. Oral Dis. 2007;13:555\u201363.","journal-title":"Oral Dis"},{"key":"5133_CR28","first-page":"817","volume":"36","author":"H Hijioka","year":"2010","unstructured":"Hijioka H, Setoguchi T, Miyawaki A, Gao H, Ishida T, Komiya S, et al. Upregulation of Notch pathway molecules in oral squamous cell carcinoma. Int J Oncol. 2010;36:817\u201322.","journal-title":"Int J Oncol"},{"key":"5133_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.bbrc.2012.06.065","volume":"424","author":"SH Lee","year":"2012","unstructured":"Lee SH, Hong HS, Liu ZX, Kim RH, Kang MK, Park NH, et al. TNFalpha enhances cancer stem cell-like phenotype via Notch-Hes1 activation in oral squamous cell carcinoma cells. Biochem Biophys Res Commun. 2012;424:58\u201364.","journal-title":"Biochem Biophys Res Commun"},{"key":"5133_CR30","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/labinvest.2013.95","volume":"93","author":"R Yoshida","year":"2013","unstructured":"Yoshida R, Nagata M, Nakayama H, Niimori-Kita K, Hassan W, Tanaka T, et al. The pathological significance of Notch1 in oral squamous cell carcinoma. Lab Invest. 2013;93:1068\u201381.","journal-title":"Lab Invest"},{"key":"5133_CR31","doi-asserted-by":"crossref","unstructured":"Inamura N, Kimura T, Wang L, Yanagi H, Tsuda M, Tanino M, et al. Notch1 regulates invasion and metastasis of head and neck squamous cell carcinoma by inducing EMT through c-Myc. Auris Nasus Larynx. 2017;44:447\u201357.","DOI":"10.1016\/j.anl.2016.08.003"},{"key":"5133_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/srep24704","volume":"6","author":"ZL Zhao","year":"2016","unstructured":"Zhao ZL, Zhang L, Huang CF, Ma SR, Bu LL, Liu JF, et al. NOTCH1 inhibition enhances the efficacy of conventional chemotherapeutic agents by targeting head neck cancer stem cell. Sci Rep. 2016;6:24704.","journal-title":"Sci Rep"},{"key":"5133_CR33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.canlet.2015.07.048","volume":"369","author":"X Yuan","year":"2015","unstructured":"Yuan X, Wu H, Xu H, Xiong H, Chu Q, Yu S, et al. Notch signaling: an emerging therapeutic target for cancer treatment. Cancer Lett. 2015;369:20\u20137.","journal-title":"Cancer Lett"},{"key":"5133_CR34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nrd4252","volume":"13","author":"ER Andersson","year":"2014","unstructured":"Andersson ER, Lendahl U. Therapeutic modulation of Notch signalling-are we there yet? Nat Rev Drug Discov. 2014;13:357\u201378.","journal-title":"Nat Rev Drug Discov"},{"key":"5133_CR35","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ygyno.2015.03.005","volume":"137","author":"I Diaz-Padilla","year":"2015","unstructured":"Diaz-Padilla I, Wilson MK, Clarke BA, Hirte HW, Welch SA, Mackay HJ, et al. A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: a study of the Princess Margaret, Chicago and California phase II consortia. Gynecol Oncol. 2015;137:216\u201322.","journal-title":"Gynecol Oncol"},{"key":"5133_CR36","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1016\/j.ejca.2015.06.115","volume":"51","author":"SA Piha-Paul","year":"2015","unstructured":"Piha-Paul SA, Munster PN, Hollebecque A, Argiles G, Dajani O, Cheng JD, et al. Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. Eur J Cancer. 2015;51:1865\u201373.","journal-title":"Eur J Cancer"},{"key":"5133_CR37","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1158\/1535-7163.MCT-17-0439","volume":"16","author":"KM Morgan","year":"2017","unstructured":"Morgan KM, Fischer BS, Lee FY, Shah JJ, Bertino JR, Rosenfeld J, et al. Gamma secretase inhibition by BMS-906024 enhances efficacy of paclitaxel in lung adenocarcinoma. Mol Cancer Ther. 2017;16:2759\u201369.","journal-title":"Mol Cancer Ther"},{"key":"5133_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-05119-0","volume":"7","author":"J Blain","year":"2017","unstructured":"Blain J, B\u00e9dard J, Thompson M, Boisvert F-M, Boucher M-J. C-terminal deletion of NOTCH1 intracellular domain (N1ICD) increases its stability but does not amplify and recapitulate N1ICD-dependent signalling. Sci Rep. 2017;7:5034.","journal-title":"Sci Rep"},{"key":"5133_CR39","doi-asserted-by":"crossref","unstructured":"Pajcini KV, Xu L, Shao L, Petrovic J, Palasiewicz K, Ohtani Y, et al. MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia. Sci Signal. 2017;10:eaam6846.","DOI":"10.1126\/scisignal.aam6846"},{"key":"5133_CR40","doi-asserted-by":"crossref","unstructured":"Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet j. 2011;17:10\u20132.","DOI":"10.14806\/ej.17.1.200"},{"key":"5133_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-017-4414-y","volume":"19","author":"M Callari","year":"2018","unstructured":"Callari M, Batra AS, Batra RN, Sammut S-J, Greenwood W, Clifford H, et al. Computational approach to discriminate human and mouse sequences in patient-derived tumour xenografts. BMC Genomics. 2018;19:19.","journal-title":"BMC Genomics"},{"key":"5133_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2012","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2012;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"5133_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1842-9","volume":"20","author":"BJ Haas","year":"2019","unstructured":"Haas BJ, Dobin A, Li B, Stransky N, Pochet N, Regev A. Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods. Genome Biol. 2019;20:213.","journal-title":"Genome Biol"},{"key":"5133_CR44","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2013","unstructured":"Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2013;30:923\u201330.","journal-title":"Bioinformatics"},{"key":"5133_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"5133_CR46","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1371\/journal.pcbi.0030039","volume":"3","author":"E Eden","year":"2007","unstructured":"Eden E, Lipson D, Yogev S, Yakhini Z. Discovering motifs in ranked lists of DNA sequences. PLoS Comput Biol. 2007;3:e39.","journal-title":"PLoS Comput Biol"},{"key":"5133_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-10-48","volume":"10","author":"E Eden","year":"2009","unstructured":"Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z. GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinforma. 2009;10:48.","journal-title":"BMC Bioinforma"},{"key":"5133_CR48","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5133_CR49","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodol). 1995;57:289\u2013300.","journal-title":"J R Stat Soc Ser B (Methodol)"},{"key":"5133_CR50","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1158\/2159-8290.CD-13-0830","volume":"4","author":"A Stoeck","year":"2014","unstructured":"Stoeck A, Lejnine S, Truong A, Pan L, Wang H, Zang C, et al. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma. Cancer Discov. 2014;4:1154\u201367.","journal-title":"Cancer Discov"},{"issue":"15_suppl","key":"5133_CR51","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1200\/JCO.2019.37.15_suppl.1064","volume":"37","author":"EC Broner","year":"2019","unstructured":"Broner EC, Alpert G, Gluschnaider U, Mondshine A, Solomon O, Sloma I, et al. AL101 mediated tumor inhibition in notch-altered TNBC PDX models. J Clin Oncol. 2019;37(15_suppl):1064.","journal-title":"J Clin Oncol"},{"issue":"13 Supplement","key":"5133_CR52","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1158\/1538-7445.AM2019-4885","volume":"79","author":"R Ferrarotto","year":"2019","unstructured":"Ferrarotto R, Alpert G, Gluschnaider U, Rauch R, Mondshine A, Solomon O, et al. Abstract 4885: AL101 mediated tumor inhibition in Notch mutated ACC PDX models. Cancer Res. 2019;79(13 Supplement):4885.","journal-title":"Cancer Res"},{"key":"5133_CR53","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/biom.12647","volume":"73","author":"PK Kimes","year":"2017","unstructured":"Kimes PK, Liu Y, Neil Hayes D, Marron JS. Statistical significance for hierarchical clustering. Biometrics. 2017;73:811\u201321.","journal-title":"Biometrics"},{"key":"5133_CR54","doi-asserted-by":"publisher","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","volume":"45","author":"M Kanehisa","year":"2016","unstructured":"Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2016;45:D353\u201361.","journal-title":"Nucleic Acids Res"},{"issue":"suppl_1","key":"5133_CR55","doi-asserted-by":"publisher","first-page":"D674","DOI":"10.1093\/nar\/gkn653","volume":"37","author":"CF Schaefer","year":"2008","unstructured":"Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, et al. PID: the Pathway Interaction Database. Nucleic Acids Res. 2008;37(suppl_1):D674\u20139.","journal-title":"Nucleic Acids Res"},{"key":"5133_CR56","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462:108\u201312.","journal-title":"Nature"},{"key":"5133_CR57","doi-asserted-by":"crossref","unstructured":"Geman D, d\u2019Avignon C, Naiman DQ, Winslow RL. Classifying gene expression profiles from pairwise mRNA comparisons. Stat Appl Genet Mol Biol. 2004;3:Article19.","DOI":"10.2202\/1544-6115.1071"},{"key":"5133_CR58","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1093\/bioinformatics\/bti631","volume":"21","author":"AC Tan","year":"2005","unstructured":"Tan AC, Naiman DQ, Xu L, Winslow RL, Geman D. Simple decision rules for classifying human cancers from gene expression profiles. Bioinformatics. 2005;21:3896\u2013904.","journal-title":"Bioinformatics"},{"key":"5133_CR59","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1093\/bioinformatics\/bti631","volume":"21","author":"AC Tan","year":"2005","unstructured":"Tan AC, Naiman DQ, Xu L, Winslow RL, Geman D. Simple decision rules for classifying human cancers from gene expression profiles. Bioinforma (Oxf, Engl). 2005;21:3896\u2013904.","journal-title":"Bioinforma (Oxf, Engl)"},{"key":"5133_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma. 2013;14:7.","journal-title":"BMC Bioinforma"},{"key":"5133_CR61","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1038\/leu.2017.90","volume":"31","author":"F Pozzo","year":"2017","unstructured":"Pozzo F, Bittolo T, Vendramini E, Bomben R, Bulian P, Rossi FM, et al. NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. Leukemia. 2017;31:2407\u201315.","journal-title":"Leukemia"},{"key":"5133_CR62","doi-asserted-by":"publisher","first-page":"e6040","DOI":"10.1371\/journal.pone.0006040","volume":"4","author":"J Phuchareon","year":"2009","unstructured":"Phuchareon J, Ohta Y, Woo JM, Eisele DW, Tetsu O. Genetic profiling reveals cross-contamination and misidentification of 6 adenoid cystic carcinoma cell lines: ACC2, ACC3, ACCM, ACCNS, ACCS and CAC2. PLoS One. 2009;4:e6040.","journal-title":"PLoS One"},{"key":"5133_CR63","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4103\/2468-5585.200513","volume":"2","author":"N-N Liu","year":"2017","unstructured":"Liu N-N, Zhang S-L, Chen W. The cross-contaminated cell lines of adenoid cystic carcinoma: a crucial concern. Transl Surg. 2017;2:10\u20133.","journal-title":"Transl Surg"},{"key":"5133_CR64","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.oraloncology.2014.06.012","volume":"50","author":"J Li","year":"2014","unstructured":"Li J, Perlaky L, Rao P, Weber RS, El-Naggar AK. Development and characterization of salivary adenoid cystic carcinoma cell line. Oral Oncol. 2014;50:991\u20139.","journal-title":"Oral Oncol"},{"key":"5133_CR65","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.oraloncology.2019.09.005","volume":"98","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Gao R, Cao C, Forbes L, Li J, Freeberg S, et al. MYB-activated models for testing therapeutic agents in adenoid cystic carcinoma. Oral Oncol. 2019;98:147\u201355.","journal-title":"Oral Oncol"},{"key":"5133_CR66","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.oraloncology.2018.10.012","volume":"87","author":"KA Warner","year":"2018","unstructured":"Warner KA, Oklejas AE, Pearson AT, Zhang Z, Wu W, Divi V, et al. UM-HACC-2A: MYB-NFIB fusion-positive human adenoid cystic carcinoma cell line. Oral Oncol. 2018;87:21\u20138.","journal-title":"Oral Oncol"},{"key":"5133_CR67","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/(SICI)1097-0215(19990531)81:5<793::AID-IJC21>3.0.CO;2-4","volume":"81","author":"L Queimado","year":"1999","unstructured":"Queimado L, Lopes C, Du F, Martins C, Fonseca I, Bowcock AM, et al. In vitro transformation of cell lines from human salivary gland tumors. Int J Cancer. 1999;81:793\u20138.","journal-title":"Int J Cancer"},{"key":"5133_CR68","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jmoldx.2016.07.012","volume":"19","author":"S Kadri","year":"2017","unstructured":"Kadri S, Long BC, Mujacic I, Zhen CJ, Wurst MN, Sharma S, et al. Clinical validation of a next-generation sequencing genomic oncology panel via cross-platform benchmarking against established amplicon sequencing assays. J Mol Diagn. 2017;19:43\u201356.","journal-title":"J Mol Diagn"},{"key":"5133_CR69","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1158\/1078-0432.CCR-14-1348","volume":"21","author":"K Wang","year":"2015","unstructured":"Wang K, Zhang Q, Li D, Ching K, Zhang C, Zheng X, et al. PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a \u03b3-secretase inhibitor. Clin Cancer Res. 2015;21:1487\u201396.","journal-title":"Clin Cancer Res"},{"key":"5133_CR70","doi-asserted-by":"publisher","first-page":"18261","DOI":"10.1073\/pnas.0606108103","volume":"103","author":"T Palomero","year":"2006","unstructured":"Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA. 2006;103:18261\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5133_CR71","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1182\/blood-2007-12-130096","volume":"112","author":"ML Sulis","year":"2008","unstructured":"Sulis ML, Williams O, Palomero T, Tosello V, Pallikuppam S, Real PJ, et al. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood. 2008;112:733\u201340.","journal-title":"Blood"},{"key":"5133_CR72","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1097\/PAS.0000000000000945","volume":"41","author":"DP Sajed","year":"2017","unstructured":"Sajed DP, Faquin WC, Carey C, Severson EA, A HA, C AJ, et al. Diffuse staining for activated NOTCH1 correlates with NOTCH1 mutation status and is associated with worse outcome in adenoid cystic carcinoma. Am J Surg Pathol. 2017;41:1473\u201382.","journal-title":"Am J Surg Pathol"},{"key":"5133_CR73","doi-asserted-by":"crossref","unstructured":"Schubert AD, Zamuner FT, London NR, Zhavoronkov A, Mehra R, Hoque MO, et al. Role of the NOTCH signaling pathway in head and neck cancer. In: Burtness B, Golemis EA, editors. Molecular determinants of head and neck cancer. Cham: Springer International Publishing; 2018. p. 229\u201348.","DOI":"10.1007\/978-3-319-78762-6_8"},{"key":"5133_CR74","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1158\/1078-0432.CCR-15-2208","volume":"22","author":"A Panaccione","year":"2016","unstructured":"Panaccione A, Chang MT, Carbone BE, Guo Y, Moskaluk CA, Virk RK, et al. NOTCH1 and SOX10 are essential for proliferation and radiation resistance of cancer stem-like cells in adenoid cystic carcinoma. Clin Cancer Res. 2016;22:2083\u201395.","journal-title":"Clin Cancer Res"},{"key":"5133_CR75","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.anndiagpath.2013.10.001","volume":"18","author":"D Bell","year":"2014","unstructured":"Bell D, Hanna EY, Miele L, Roberts D, Weber RS, El-Naggar AK. Expression and significance of notch signaling pathway in salivary adenoid cystic carcinoma. Ann Diagn Pathol. 2014;18:10\u20133.","journal-title":"Ann Diagn Pathol"},{"key":"5133_CR76","doi-asserted-by":"publisher","first-page":"950","DOI":"10.15252\/emmm.201607265","volume":"9","author":"Y Ran","year":"2017","unstructured":"Ran Y, Hossain F, Pannuti A, Lessard CB, Ladd GZ, Jung JI, et al. gamma-Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct. EMBO Mol Med. 2017;9:950\u201366.","journal-title":"EMBO Mol Med"},{"key":"5133_CR77","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3389\/fonc.2018.00460","volume":"8","author":"V Sosa Iglesias","year":"2018","unstructured":"Sosa Iglesias V, Theys J, Groot AJ, Barbeau LMO, Lemmens A, Yaromina A, et al. Synergistic effects of NOTCH\/gamma-secretase inhibition and standard of care treatment modalities in non-small cell lung cancer cells. Front Oncol. 2018;8:460.","journal-title":"Front Oncol"},{"key":"5133_CR78","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0022034511401407","volume":"90","author":"L Dong","year":"2011","unstructured":"Dong L, Wang YX, Li SL, Yu GY, Gan YH, Li D, et al. TGF-beta1 promotes migration and invasion of salivary adenoid cystic carcinoma. J Dent Res. 2011;90:804\u20139.","journal-title":"J Dent Res"},{"key":"5133_CR79","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/ng.3502","volume":"48","author":"Y Drier","year":"2016","unstructured":"Drier Y, Cotton MJ, Williamson KE, Gillespie SM, Ryan RJ, Kluk MJ, et al. An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. Nat Genet. 2016;48:265\u201372.","journal-title":"Nat Genet"},{"key":"5133_CR80","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.scr.2017.05.002","volume":"21","author":"A Panaccione","year":"2017","unstructured":"Panaccione A, Zhang Y, Ryan M, Moskaluk CA, Anderson KS, Yarbrough WG, et al. MYB fusions and CD markers as tools for authentication and purification of cancer stem cells from salivary adenoid cystic carcinoma. Stem Cell Res. 2017;21:160\u20136.","journal-title":"Stem Cell Res"},{"key":"5133_CR81","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1600-0714.2011.01096.x","volume":"41","author":"S Fujita","year":"2012","unstructured":"Fujita S, Ikeda T. Cancer stem-like cells in adenoid cystic carcinoma of salivary glands: relationship with morphogenesis of histological variants. J Oral Pathol Med. 2012;41:207\u201313.","journal-title":"J Oral Pathol Med"},{"key":"5133_CR82","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18:407\u201318.","journal-title":"Nat Rev Cancer"},{"key":"5133_CR83","doi-asserted-by":"crossref","unstructured":"Kondo J, Inoue M. Application of cancer organoid model for drug screening and personalized therapy. Cells. 2019;8:470.","DOI":"10.3390\/cells8050470"},{"key":"5133_CR84","doi-asserted-by":"publisher","first-page":"e0171341","DOI":"10.1371\/journal.pone.0171341","volume":"12","author":"XL Gao","year":"2017","unstructured":"Gao XL, Wu JS, Cao MX, Gao SY, Cen X, Jiang YP, et al. Cytokeratin-14 contributes to collective invasion of salivary adenoid cystic carcinoma. PLoS One. 2017;12:e0171341.","journal-title":"PLoS One"},{"key":"5133_CR85","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/cpt.354","volume":"99","author":"E Izumchenko","year":"2016","unstructured":"Izumchenko E, Meir J, Bedi A, Wysocki PT, Hoque MO, Sidransky D. Patient-derived xenografts as tools in pharmaceutical development. Clin Pharmacol Ther. 2016;99:612\u201321.","journal-title":"Clin Pharmacol Ther"},{"key":"5133_CR86","doi-asserted-by":"publisher","first-page":"e9094","DOI":"10.1371\/journal.pone.0009094","volume":"5","author":"M Aste-Am\u00e9zaga","year":"2010","unstructured":"Aste-Am\u00e9zaga M, Zhang N, Lineberger JE, Arnold BA, Toner TJ, Gu M, et al. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. PLoS One. 2010;5:e9094.","journal-title":"PLoS One"},{"key":"5133_CR87","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1158\/1940-6207.CAPR-15-0316","volume":"9","author":"EM Rettig","year":"2016","unstructured":"Rettig EM, Talbot CC Jr, Sausen M, Jones S, Bishop JA, Wood LD, et al. Whole-genome sequencing of salivary gland adenoid cystic carcinoma. Cancer Prev Res (Philos). 2016;9:265\u201374.","journal-title":"Cancer Prev Res (Philos)"},{"key":"5133_CR88","doi-asserted-by":"publisher","first-page":"S663","DOI":"10.1016\/j.annonc.2020.08.1034","volume":"31","author":"R Ferrarotto","year":"2020","unstructured":"Ferrarotto R, Wirth LJ, Muzaffar J, Rodriguez CP, Xia B, Perez CA, et al. 919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent\/metastatic (R\/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut). Ann Oncol. 2020;31:S663.","journal-title":"Ann Oncol"},{"key":"5133_CR89","doi-asserted-by":"publisher","first-page":"S1222","DOI":"10.1016\/j.annonc.2021.08.1732","volume":"32","author":"R Ferrarotto","year":"2021","unstructured":"Ferrarotto R, Rauch R, Leibovich T, Shitrit A, Solomon O, Herz E, et al. 1789P The gamma secretase inhibitor AL101 combined with other drugs for dual targeting of Notch dysregulated tumors. Ann Oncol. 2021;32:S1222.","journal-title":"Ann Oncol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05133-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05133-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05133-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T19:58:38Z","timestamp":1727726318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05133-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":89,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["5133"],"URL":"https:\/\/doi.org\/10.1038\/s41419-022-05133-9","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"assertion":[{"value":"5 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EH, AY, OS, RR, AM, MM, TL-R, MD, and JK are affiliated with Ayala Pharmaceuticals. RF, JCA, and EI are consultants to Ayala Pharmaceuticals. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"678"}}